Loading clinical trials...
Loading clinical trials...
A Phase I Study of Pembrolizumab Anti PD-1 Monoclonal Antibody in Combination With Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Conditions
Interventions
Pembrolizumab
Radiotherapy
Start Date
August 1, 2017
Primary Completion Date
August 1, 2019
Completion Date
August 1, 2019
Last Updated
July 28, 2021
NCT07485114
NCT06066138
NCT05098132
NCT06284317
NCT06731413
NCT06687369
Lead Sponsor
Prof Corinne Faivre-Finn
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions